Owkin Announces Collaboration with Bristol Myers Squibb

Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence (AI) capabilities to design clinical trials for Bristol Myers Squibb. The collaboration will initially focus on cardiovascular diseases, and has the potential to extend into projects in other therapeutic areas.

Read more about the collaboration here.